The "me better" strategy has always been a great story for pharmaceutical companies.
Apparatus
-
-
The US FDA approved the ADC drug gosatumumab (Trodelvy) for the treatment of patients with hormone receptor-positive, HER2-negative breast cancer. In the trial, the drug significantly extended the overall survival of patients and reduced the risk of death by 21%.
-
Scientists from MIT designed a microfluidic device to capture and count circulating plasma cells in small samples of blood. This technique can only be carried out through routine blood drawing, which is expected to reduce the pain of patients' myeloma testing.
-
Under the terms of the collaboration agreement, GenKOre will receive up to US$300 million, including upfront fees, fees for exercising its option, and milestone payments for successfully reaching development and commercialisation milestones against two in vivo disease targets.
-
Apparatus
Angry FDA & CDC: $5 Billion Bivalent Moderna New Crown Vaccine Not As Effective As Monovalent
Was the omission of key data intentional or unintentional?
-
Apparatus
New Discovery: Drug For Parkinson's Disease That May Reduce Chemotherapy Side Effects And Boost Cancer-Fighting Power!
A new study has found that Istradefylline, a drug already approved to treat Parkinson's disease, not only reduces the toxicity associated with the chemotherapy drug cisplatin, but also boosts its cancer-fighting power, promising a potential treatment to reduce the side effects of chemotherapy.
-
Apparatus
Georgia Institute of Technology 3D printing heart valve model to improve the success rate of valve replacement
It is reported that researchers from Georgia Institute of Technology and Piemonte Heart Institute are using customized 3D printed heart valve models based on patients' heart CT scanning to improve the success rate of transcatheter aortic valve replacement (TAVR) surgery. Their aim is to avoid perivalvular leakage. This research has been published in JACC: Cardiovascular Imaging.
-
Prior to the granting of marketing authorisation by the MHRA, Biyze® had been approved by the European Commission for a number of indications and is currently the only drug approved for the treatment of MZL in Great Britain.
-
The global ADC drug market will be approximately $5.2 billion by 2021
-
Ibuprofen belongs to antipyretic and analgesic, not cold medicine.